Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

Mark J. Ratain, MD, of the University of Chicago, and Daniel Goldstein, MD, of the Rabin Medical Center, discuss the challenges of achieving cancer care value, evolution of the “more-is-better” philosophy when it comes to oncology drugs, and highlights of the First International Summit on Interventional Pharmacoeconomics.

Lymphoma

The ASCO Post Staff

Mark J. Ratain, MD, on Chronic Lymphocytic Leukemia: Making a Case for Low-Dose Ibrutinib

Mark J. Ratain, MD, of the University of Chicago, talks about why ibrutinib—which can lead to cardiotoxicities—should be studied at a lower dose for patients with chronic lymphocytic leukemia. Data suggest a reduced dose may prevent dose interruption due to adverse events and may have a better therapeutic index.

Nov

Today In Oncology

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Related Videos

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

Mark J. Ratain, MD, on Chronic Lymphocytic Leukemia: Making a Case for Low-Dose Ibrutinib

16 Million PRISM Trial Will Explore AI in Breast Cancer Screening

Axicabtagene Ciloleucel in Relapsed or Refractory Indolent Non-Hodgkin Lymphoma

Study Finds Breast Cancer Risk Varies Between Different Hormonal Contraceptives

Diminishing the National Cancer Institute Threatens Americans

Zanzalintinib Plus Atezolizumab vs Regorafenib in Previously Treated Metastatic Colorectal Cancer Without MSI-H or dMMR Tumors